ΝΟΣΟΚΟΜΕΙΑΚΑ ΧΡΟΝΙΚΑ

ΝΟΣΟΚΟΜΕΙΑΚΑ ΧΡΟΝΙΚΑ, ΤΟΜΟΣ 72, TEYXOΣ 1−3, 2010 5752. WE Evans. Pharmacogenetics of TPMT and thiopu−rine therapy. Ther Drug Monit 2004; 26:186−191.53. WE Evans, YY Hon, L bomgaars, S Coutre et al.Preponderance of thiopurine methyltransferasedeficiency and heterozygosity among patients in−tolerant to mercaptopurine or azathioprine. J ClinOncol 2001; 19:2293−2301.54. R Ngasubramanian, F Innoccenti, IU Ratain. Phar−macogenetics in cancer treatment. Annu Rev Med2003; 54:437−452.55. Κ Αraki, K Fujita, Y Ando,F Nagashima et al. Pharma−cogenetic impact of polymorphisms in the codingregions of the UGT1A1 gene on SN−38 glucuronida−tion in Japanese patients with cancer. Cancer Sci2006; 97:1255−1259.56. ML Maitland, K Vasisht, M J Ratain. TPMT, UGT1A1and DPYD: genotyping to ensure cancer therapy?Trends Pharmacol Sc 2006; 27:432−437.57. http://www.fda.gov58. ΑΒvan Kuilenburg, JW Baars, R Meinsna, AH vanGennip. Lethal 5−FU toxicity associated with anovel mutation in the DPD gene. Ann Oncol 2003;14:341−342.59. ES Collie−Duguid, MC Etienne, S Milano,HL McLeod. Known variant DPYD alleles don’t explainDPD deficiency in cancer patients. Pharmacoge−netics 2000; 10:217−233.60. N Frickhofen, FJ Beck, B Jurg, HG Fuhr et al.Capecitabine can induce acute coronary syndromesimilar to 5−FU. Ann Oncol 2002; 13:797−801.61. S Rodriguez− Novoa, P Barreiro, A Rendon et al.Plasma levels of atazanavir and the risk of hyper−bilirubinaemia are predicted by polymorphisms ofthe multi drug resistance gene 1. Clin Infect Dis2006; 42:291−295.62. U Brikmann, I Roots, M Eichelhaum. Pharmacoge−netics of the human drug−transporter gene MDR1:impact of polymorphisms on pharmacotherapy.Drug Disc Today 2001; 6:835−839.63. LJ Palmer, ES Silverman, ST Weiss, JM Drazen. Phar−macogenetics of asthma. Am J Respir Crit CareMed 2002; 165:861−866.64. ME Wechsler, E Israel. How pharmacogenomicswill play a role in the management of asthma. AmJ Respir Crit Care Med 2005; 172:12−18.65. ΕΜ Penas−Lledo, P Dorado, M Caceres, A Rubia,A Lerena. Association between polymorphisms inserotonin receptor 2A gene and schizophrenia: rel−evance for treatment with antipsychotic drugs. ClinChem Lab Med 2007; 45:835−838.66. MJ Arranz, J de Leon. Pharmacogenetics and phar−macogenomics of schizophrenia: A review of lastdecade research. Molecul Psychiatry 2007; 12:707−747.67. FA Sayed−Tabtabei, BA Oostra, A Isaacs, CM vanDuijn, JCM Witterman. ACE polymorphisms. A re−view. Circul Research 2006; 98:1123.68. KR Acharya, ED Sturrock, JF Riordan, MRW Ehlers.ACE revised: a new target for structure−based drugdesign. Nature 2003; 2:831−901.69. WH Tang, MD Wilson, H Randall. Impact of ACEgene polymorphism on neurohormonal responsesto high versus low−dose enalapril in advancedheart failure. Amer H J 2004; 148:889−894.70. M Killiszek, B Burzynska, G Styznski, M Maciaget al. A1166 polymorphism of AT1R gene altersthe endothelial response to statin treatment. ClinChem Lab Med 2007; 45:839−842.71. JA Riancho, MT Zarrabeitia, C Valero, C Sanudo etal. A gene to gene interaction between aromataseand estrogen receptors influences bone mineraldensity. Eur J Endocrinol 2006;155:53−59.72. DM Herrigton, TD Howard, GA Hawkins et al. Es−trogen receptor polymorphisms and effects of es−trogen replacement on HDL cholesterol level inwomen with coronary disease. N Engl J Med 2002;346:967−974.73. A Ring, M Dowsett. Endocrine related cancer. Can−cer 2004; 11:643−58.74. KI Pritchard, LE Shepherd, PP O’Maley, IL Andrulis,D Tu, VH Bramwell, MN Levine. HER2 and respon−siveness of breast cancer to adjutant chemothera−py. N Engl J Med 2006; 354:2103−2111.75. GL Plosker, SJ Keam. Trastuzumab: A review of itsuse in the management of HER2 positive meta−static and early stage breast cancer. Drugs 2006;66:449−475.76. S Menard, P Caslini, M Campoglio, S Pupas, RAgresti, E Tagliabue. HER2 overexpression in vari−ous tumor type focusing on its relationship to thedevelopment of invasive breast cancer. Ann Oncol2001; 12S:1519.77. T Kirkegaard, LM Mc Glynn, FM Campell, S Mulleret al. Amplified in breast cancer 1 human EGFR–positive tumors of tamoxifen−treated breast can−cer patients. Vlin Cancer Res 2007; 13:1405−1411.78. T Holbro, G Civenni, NE Hynes. The ErbB receptorsand their role in cancer progression. Exp Cell Res2003; 99−110.